10:43 AM EDT, 07/15/2025 (MT Newswires) -- Kairos Pharma ( KAPA ) shares were up about 75% in recent Tuesday trading after the company reported positive safety results from an ongoing phase 2 trial of ENV-105 in advanced prostate cancer.

"The favorable safety profile observed in this Phase 2 study is encouraging," said Chief Executive John Yu.

Kairos said interim safety trial analysis showed ENV-105 was well tolerated when combined with standard of care hormone therapy, apalutamide, from the first ten patients, with no dose-limiting toxicities or unexpected adverse events.

The company said interim efficacy data are expected in September. It also plans to discuss with regulators on the design of a potential phase 3 trial.

Price: 1.20, Change: +0.51, Percent Change: +75.01